TG THERAPEUTICS, INC.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $TGTX in the last 7 days.
B. Riley analyst Mayank Mamtani highlighted top biotech picks ahead of 3Q26 earnings, including Axsome Therapeutics (AXSM), Cytokinetics (CYTK), Eton Pharmaceuticals (ETON), Harrow (HROW), TG Therapeutics (TGTX), and Zymeworks (ZYME). The analyst provided price targets and revenue projections for each, noting macroeconomic challenges for small and mid-cap biotech stocks.
Insiders at Guardant Health (GH), Geo Group (GEO), Tower Semiconductor (TSEM), TG Therapeutics (TGTX), and GigaCloud (GCT) sold shares. GH saw $3.3M in sales from five insiders. GEO's SVP sold $371K, TSEM's director sold $49K, TGTX's director sold $275K, and GCT's director sold $158K.
TG Therapeutics (TGTX) shares rose 5% after Bank of America raised its price target to $20 from $17, despite an 'Underperform' rating. The company launched a mid-stage trial for Briumvi in treatment-resistant schizophrenia. Analysts focus on Q2 U.S. revenue for Briumvi, with estimates around $229M, exceeding the company's $220M guidance. TGTX has gained 95% year-to-date.
Recent TGTX coverage spans financial news, market movers and earnings.
In the last 30 days, TGTX insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($275K). The most active reporter was Charney Laurence N with 1 filing.
Upcoming data could drive price action.
Insider sell may weigh on sentiment for the biotech.
Analyst price‑target hike and new trial could boost short‑term demand.
Potential approval and dosing simplification could boost sales and market share in MS.
Minor dilution of insider ownership; unlikely to move price materially.
AlphAI scores every news story that mentions TGTX with an AI model for sentiment and relevance, and aggregates insider trades from TG THERAPEUTICS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
B. Riley analyst Mayank Mamtani highlighted top biotech picks ahead of 3Q26 earnings, including Axsome Therapeutics (AXSM), Cytokinetics (CYTK), Eton Pharmaceuticals (ETON), Harrow (HROW), TG Therapeutics (TGTX), and Zymeworks (ZYME). The analyst provided price targets and revenue projections for each, noting macroeconomic challenges for small and mid-cap biotech stocks.
3 min readInsiders at Guardant Health (GH), Geo Group (GEO), Tower Semiconductor (TSEM), TG Therapeutics (TGTX), and GigaCloud (GCT) sold shares. GH saw $3.3M in sales from five insiders. GEO's SVP sold $371K, TSEM's director sold $49K, TGTX's director sold $275K, and GCT's director sold $158K.
1 min readTG Therapeutics (TGTX) shares rose 5% after Bank of America raised its price target to $20 from $17, despite an 'Underperform' rating. The company launched a mid-stage trial for Briumvi in treatment-resistant schizophrenia. Analysts focus on Q2 U.S. revenue for Briumvi, with estimates around $229M, exceeding the company's $220M guidance. TGTX has gained 95% year-to-date.
1 min readTG Therapeutics (TGTX) aims for a $1B quarterly run rate by year-end, driven by BRIUMVI's market share gains in multiple sclerosis. The company reports increased treatment-naive patient use and plans a simplified dosing approach. Subcutaneous BRIUMVI is in Phase 3 trials, targeting a 2028 approval. Weiss expects pivotal data by year-end or early 2024.
2 min readCharney Laurence N sold 5,000 shares of TG THERAPEUTICS, INC. (TGTX) at $54.96 ($0.27M total) on 2026-09-10.
1 min readTG Therapeutics (TGTX) shares surged 85% YTD after a Betaville report suggested a potential takeover by a U.S. biopharma company. TGTX reported Q2 revenue of $227.7M for BRIUMVI, up 64% YoY, and raised its 2026 revenue target to $950M. Analysts maintain a 'Moderate Buy' rating with a $64 price target, implying 17% upside.
2 min readTG Therapeutics (TGTX) shares rose 11.9% as investors reassessed its growth outlook. The company raised 2026 revenue guidance for BRIUMVI and reported progress in its simplified dosing program. It also expects data from a Phase 3 trial of subcutaneous BRIUMVI by early 2027. Institutional investors have recently increased their positions in the stock.
2 min readUS equities show sharp divergence midday. Robinhood (HOOD) +13.28%, Moderna (MRNA) +12.01%, Hut 8 (HUT) -9.51%, Alibaba (BABA) -7.01%. Other movers include TG Therapeutics (TGTX), USA Rare Earth (USAR), Infleqtion (INFQ), OSI Systems (OSIS), Telix Pharmaceuticals (TLX), Seabridge Gold (SA).
2 min readTG Therapeutics (TGTX) stock rose 5.9% to $53.55, recovering from a post-earnings selloff. Q2 revenue was $240M, up 70% YoY, and the company raised its 2026 revenue target to $950M. Despite an EPS miss, analysts remain bullish with price targets above current levels. The broader market's positive tone also supported the rally.
1 min readSimply Wall St reports TG Therapeutics (TGTX) posted Q2 2026 revenue of $240.34 million versus $141.15 million a year earlier, while net income fell to $7.78 million from $28.19 million. The company raised full-year 2026 total global revenue guidance to about $950 million, citing improved commercial trajectory.
4 min read
